Eisai
TSE:4523equityPrevious close
4,953
Open
4,958
Day's range
4,903 – 4,990
52-week range
3,660 – 5,276
Volume
2,095,500
Currency
JPY
About Eisai
Eisai Co., Ltd. is a Japanese pharmaceutical company specializing in the research, development, and marketing of prescription medicines. The company focuses on treatments for neurological disorders, oncology, and other therapeutic areas. Eisai operates primarily in Japan but has a significant global presence, including partnerships in Europe and the United States.
Why investors watch it
Eisai is closely watched by foreign investors due to its strong position in the pharmaceutical sector, particularly in neurodegenerative disease treatments. As one of Japan's leading drugmakers, it offers exposure to the domestic healthcare market while actively expanding its global footprint through strategic partnerships and investments. Recent collaborations with UK institutions highlight its commitment to innovation and international growth.
News
All news →No news found for Eisai.
Press Releases
All releases →LEQEMBI(R) Pen (Subcutaneous Formulation of LEQEMBI(R)) Approved in Japan for the Treatment of Early Alzheimer's Disease
18 Sept 2026
JCN NewswireEisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)
15 Sept 2026
JCN Newswireエーザイ、大阪府と「認知症及び MCI (軽度認知障がい)の啓発等に係る連携・協力に関する協定」を締結
14 Sept 2026
JCN NewswireLEQEMBI(R) (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China
8 Sept 2026
JCN NewswireCanada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI(R) (lecanemab) for Early Alzheimer's Disease
8 Sept 2026
JCN Newswireカナダ医薬品庁、早期アルツハイマー病治療剤「レケンビ(R)」（レカネマブ）の公的償還を支持する最終勧告を公表
1 Sept 2026
JCN NewswireLEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
27 Aug 2026
JCN Newswireエーザイ、抗 Aβ抗体「レケンビ(R)」の皮下注射製剤「LEQEMBI IQLIK(R)」を早期アルツハイマー病に対する初期療法として米国で新発売
25 Aug 2026
JCN NewswirePfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
27 Jul 2026
JCN Newswireファイザーとエーザイ、片頭痛の予防（発症抑制）・治療薬「ナルティーク(R)」のコ・プロモーションを開始
27 Jul 2026
JCN NewswireMarketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
17 Jul 2026
JCN Newswireエーザイ、自社創製の不眠症治療薬レンボレキサントの販売承認申請を欧州医薬品庁が受理
16 Jul 2026
Company Milestones
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
Market data is indicative and delayed 15–20 min. Not investment advice.